Chronic obstructive pulmonary disease
-
Upload
ranjita-pallavi -
Category
Health & Medicine
-
view
122 -
download
4
Transcript of Chronic obstructive pulmonary disease
![Page 1: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/1.jpg)
COPD – Harrison Club
Internal Medicine PGY-1Ranjita Pallavi
![Page 2: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/2.jpg)
Definition
Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease with some significant extrapulmonary effects that may contribute to the severity in individual patients. Its pulmonary component is characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and associated with an abnormal inflammatory response of the lung to noxious particles or gases.
![Page 3: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/3.jpg)
Asthma and COPD
![Page 4: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/4.jpg)
Risk factors
Smoking
Airway Responsiveness and COPD
Respiratory infections
Occupational exposure
Ambient Air Pollution
Passive smoke exposure
Genetic Considerations
![Page 5: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/5.jpg)
Alpha 1 Antitrypsin Deficiency Allelles: M,S,Z and Null
Most common deficiency PiZ
1-2% of COPD patients with severe
alpha 1 AT deficiency
Early onset COPD
Variability among PiZ individuals:
explained by Smoking/Asthma/COPD
Risk in PiMZ individuals
![Page 6: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/6.jpg)
In patients of Caucasian descent who develop COPD at a young age (< 45 years) or who have a strong family history of the disease, it may be valuable to identify coexisting alpha-1antitrypsin deficiency. This could lead to family screening or appropriate
Assessment and Monitoring
![Page 7: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/7.jpg)
Natural History
![Page 8: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/8.jpg)
Pathophysiology
Airflow Obstruction
Hyperinflation
Gas exchange
![Page 9: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/9.jpg)
Pathology
Large Airways
Small Airways
Lung Parenchyma
Large AirwaysSmall AirwaysLung Parenchyma
![Page 10: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/10.jpg)
Pathogenesis
Elastase:Antielastase Hypothesis
Large AirwaysSmall AirwaysLung Parenchyma
![Page 11: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/11.jpg)
Clinical Presentation
History
Physical Examination
Lab Findings
Large AirwaysSmall AirwaysLung Parenchyma
![Page 12: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/12.jpg)
The diagnosis and staging of COPD require what two spirometric measures?
Severity Classification Question
![Page 13: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/13.jpg)
FEV1/FVC
FEV1
Severity Classification
![Page 14: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/14.jpg)
FEV1/FVC < 0.7.
Severity Classification
The diagnosis of COPD is confirmed when a post-bronchodilator:
![Page 15: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/15.jpg)
GOLD Criteria for COPD
Large AirwaysSmall AirwaysLung Parenchyma
![Page 16: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/16.jpg)
Spirometric classification has proved useful in predicting health status, utilization of healthcare resources, research, development of exacerbations and mortality.
Severity Classification
![Page 17: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/17.jpg)
In advanced COPD, measurement of arterial blood gases while the patient is breathing air is important. This test should be performed in stable patients with FEV1 < 50% predicted or with clinical signs suggestive of respiratory failure or right heart failure.
Assessment and Monitoring
![Page 18: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/18.jpg)
Radiographic Studies
Chest X ray
CT Chest
Large AirwaysSmall AirwaysLung Parenchyma
![Page 19: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/19.jpg)
Clinical Presentation
History
Physical Examination
Lab Findings
Large AirwaysSmall AirwaysLung Parenchyma
![Page 20: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/20.jpg)
The Public Health Service recommends a five-step program (the five A’s) for smoking cessation intervention. After ASK, ADVISE, ASSESS, and ASSIST, what is the last step in the GOLD guidelines?
Assessment and Monitoring Question
![Page 21: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/21.jpg)
ASK Systematically identify all tobacco users at
every visit
ADVISE Strongly urge all tobacco users to quit
ASSESS Determine willingness to make a quit
attempt.
ASSIST Aid the patient in quitting
ARRANGE Schedule follow-up contact
Assessment and MonitoringSmoking Cessation Strategy
![Page 22: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/22.jpg)
True or False: Influenza vaccine and pneumococcal polysaccharide vaccine are recommended for all COPD patients.
Managing Stable Disease
![Page 23: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/23.jpg)
False: In COPD patients, influenza vaccines canreduce serious illness. Pneumococcal polysaccharide vaccine is recommended for COPD patients 65 yearsand older and for COPD patients younger than age 65 with an FEV1 < 40% predicted
Managing Stable Disease
![Page 24: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/24.jpg)
Nutritional support had no significant effect on anthropometric measures, lung function or exercise capacity in patients with stable COPD. Although some quality of life indices gave significant findings, these results were from a single small unblinded study and restricted to certain domains of health status measurements. More work in this particular area is needed to establish whether supplementation can lead to subjective benefits in quality of life.
Cochrane Database, 2007
Managing Stable DiseaseNutrition
![Page 25: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/25.jpg)
Managing Stable DiseasePharmacotherapy
Anticholinergic Agents
Beta-2 Agonists
Inhalational Corticosteroids
Oral Corticosteroids
Theophylline
Oxygen
N-acetyl cysteine
Alpha-1 AT augmentation therapy
![Page 26: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/26.jpg)
Managing COPD Exacerbations
Patient Assessment
Identify Precipitating Causes
Bronchodilators
Corticosteroids
Antibiotics
Oxygen
Mechanical Ventilator Support
![Page 27: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/27.jpg)
Managing Stable DiseaseNon Pharmacologic Measures
General Medical Care
Pulmonary Rehabilitation
Lung Volume Reduction Surgery
Lung Transplantation
![Page 28: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/28.jpg)
Rehabilitation relieves dyspnea and fatigue, improves emotional function and enhances patients’ sense of control over their condition. These improvements are moderately large and clinically significant. Rehabilitation forms an important component of the management of COPD.
Cochrane Database, 2007
Managing Stable DiseasePulmonary Rehabilitation
![Page 29: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/29.jpg)
The long-term administration of oxygen (> 15 hours per day) to patients with chronic respiratory failure has been shown to increase survival. It can also have a beneficial effect on hemodynamics, hematologic characteristics, exercise capacity, lung mechanics and mental state.
Managing Stable Disease Oxygen Therapy
![Page 30: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/30.jpg)
Long-term home oxygen therapy improved survival in a selected group of COPD patients with severe hypoxaemia (arterial PaO2 less than 55 mm Hg (8.0 kPa)). Home oxygen therapy did not appear to improve survival in patients with mild to moderate hypoxaemia or in those with only arterial desaturation at night.
Managing Stable DiseaseOxygen Therapy
![Page 31: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/31.jpg)
PaO2 < 55 mm Hg, or SaO2 < 88 %, at rest,
breathing room air.
PaO2 < 55 mm Hg, or SaO2 < 88 %, during sleep for
a patient who demonstrates an PaO2 > 56 mm Hg, or
SaO2 > 89 percent, while awake.
PaO2 < 55 mm Hg or SaO2 < 88%, during exercise
for a patient who demonstrates an PaO2 > 56 mm Hg,
or SaO2 > 89 percent during the day, while at rest.
Managing Stable Disease Oxygen Therapy
![Page 32: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/32.jpg)
PaO2 is 56-59 mm Hg or whose SaO2 = 89%, if there
is evidence of:
Dependent edema suggesting congestive heart failure;
Pulmonary hypertension or cor pulmonale, determined
by measurement of pulmonary artery pressure, gated
blood pool scan, echocardiogram, or “P” pulmonale on
EKG (P wave greater than 3 mm in standard leads II, III,
or AVF); or
Erythrocythemia with a hematocrit greater than 56
percent.
Managing Stable Disease Oxygen Therapy
![Page 33: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/33.jpg)
Managing Stable Disease
![Page 34: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/34.jpg)
Wise R, Tashkin D. AJM 2007;120:S4
Managing Stable Disease
![Page 35: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/35.jpg)
Patients with FEV1/DLco < 20% of predicted AND homogeneous (diffuse) distribution of emphysema are at high risk for death after surgery and are unlikely to benefit from lung volume reduction surgery (LVRS).
NETT. NEJM 2001;345:1075-83.
Managing Stable Disease Surgery
![Page 36: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/36.jpg)
Guidelines for Referral BODE index exceeding 5 Guidelines for Transplantation Patients with a BODE index of 7 to 10 or at least 1 of
the following: History of hospitalization for exacerbation associated
with acute hypercapnia (PCO2 exceeding 50 mm Hg) Pulmonary hypertension or cor pulmonale, or both
despite oxygen therapy. FEV1 of less than 20% and either DLCO of less than
20% or homogenous distribution of emphysema.
ISHLT Guidelines. JHeartLungTrans.2006;25:745
Managing Stable Disease Surgery
![Page 37: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/37.jpg)
What is BODE an acronym for?
Managing Stable Disease Surgery Question
![Page 38: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/38.jpg)
Celli B, et al. NEJM. 2004;350:1005
Managing Stable Disease Surgery
![Page 39: Chronic obstructive pulmonary disease](https://reader035.fdocuments.us/reader035/viewer/2022062705/55654bb0d8b42a9b4c8b4ddb/html5/thumbnails/39.jpg)
Thank You
?